Loading…

Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies

Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs ar...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2013-01, Vol.2013 (2013), p.1-9
Main Authors: Cherwonogrodzky, John W., Yu, Justin, Lillico, Dustin, Hu, Charles Chen, Chau, Damon, Yin, Junfei, Hu, Wei-Gang, Negrych, Laurel M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863
cites cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863
container_end_page 9
container_issue 2013
container_start_page 1
container_title BioMed research international
container_volume 2013
creator Cherwonogrodzky, John W.
Yu, Justin
Lillico, Dustin
Hu, Charles Chen
Chau, Damon
Yin, Junfei
Hu, Wei-Gang
Negrych, Laurel M.
description Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.
doi_str_mv 10.1155/2013/471346
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3591125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A373372879</galeid><sourcerecordid>A373372879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</originalsourceid><addsrcrecordid>eNqNkVtLHDEYhoMoKupV72XBG2kZ_XKYZHIjLNuDBXug2OuQyWE3Mpusk9kW--vNMHaxd81NQr6Hh5fvRegNhiuM6_qaAKbXTGDK-B46JhSzimOG93dvSo_QWc4PUE6DOUh-iI4IZQ3DBI7R_SJFn_q1HkKK1Xu3cdG6OMxuw3JVzb0PMQxPs-9pGD9_BBNi9dVth1534U-Iy9mXFJPpUtTdbB6H0CYbXD5FB1532Z293Cfo58cP94vb6u7bp8-L-V1laoChYgCGtlADl1YDBm8bLS0nZaiNEIJbRomT0gpg3tNWSNZqJ71vmSd1w-kJupm8m227dtaUjCWY2vRhrfsnlXRQ_05iWKll-qVoLTEmdRFcvgj69Lh1eVDrkI3rOh1d2maFGWc1MNLIgl5M6FJ3ToWytGI0I67mVFAqSCNG6t1EmT7l3Du_C4NBjYWpsTA1FVbo89f5d-zfegrwdgJWIVr9O_yfzRXEef0KBkZLuGf13qbH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464504289</pqid></control><display><type>article</type><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M.</creator><contributor>Byrne, Barry J.</contributor><creatorcontrib>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M. ; Byrne, Barry J.</creatorcontrib><description>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2013/471346</identifier><identifier>PMID: 23484120</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Animals ; Antibodies, Monoclonal, Murine-Derived - immunology ; Antibodies, Monoclonal, Murine-Derived - pharmacology ; Antibodies, Neutralizing - immunology ; Antibodies, Neutralizing - pharmacology ; Antibody Affinity ; Antidotes ; Antitoxins - immunology ; Antitoxins - pharmacology ; Drug therapy ; Epitopes - immunology ; Female ; Health aspects ; Mice ; Mice, Inbred BALB C ; Monoclonal antibodies ; Poisoning ; Protein Structure, Tertiary ; Ricin ; Ricin - immunology ; Ricin - toxicity</subject><ispartof>BioMed research international, 2013-01, Vol.2013 (2013), p.1-9</ispartof><rights>Copyright © 2013 Wei-Gang Hu et al.</rights><rights>COPYRIGHT 2013 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2013 Wei-Gang Hu et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</citedby><cites>FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925,37013</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23484120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Byrne, Barry J.</contributor><creatorcontrib>Cherwonogrodzky, John W.</creatorcontrib><creatorcontrib>Yu, Justin</creatorcontrib><creatorcontrib>Lillico, Dustin</creatorcontrib><creatorcontrib>Hu, Charles Chen</creatorcontrib><creatorcontrib>Chau, Damon</creatorcontrib><creatorcontrib>Yin, Junfei</creatorcontrib><creatorcontrib>Hu, Wei-Gang</creatorcontrib><creatorcontrib>Negrych, Laurel M.</creatorcontrib><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</description><subject>Animals</subject><subject>Antibodies, Monoclonal, Murine-Derived - immunology</subject><subject>Antibodies, Monoclonal, Murine-Derived - pharmacology</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Neutralizing - pharmacology</subject><subject>Antibody Affinity</subject><subject>Antidotes</subject><subject>Antitoxins - immunology</subject><subject>Antitoxins - pharmacology</subject><subject>Drug therapy</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monoclonal antibodies</subject><subject>Poisoning</subject><subject>Protein Structure, Tertiary</subject><subject>Ricin</subject><subject>Ricin - immunology</subject><subject>Ricin - toxicity</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNkVtLHDEYhoMoKupV72XBG2kZ_XKYZHIjLNuDBXug2OuQyWE3Mpusk9kW--vNMHaxd81NQr6Hh5fvRegNhiuM6_qaAKbXTGDK-B46JhSzimOG93dvSo_QWc4PUE6DOUh-iI4IZQ3DBI7R_SJFn_q1HkKK1Xu3cdG6OMxuw3JVzb0PMQxPs-9pGD9_BBNi9dVth1534U-Iy9mXFJPpUtTdbB6H0CYbXD5FB1532Z293Cfo58cP94vb6u7bp8-L-V1laoChYgCGtlADl1YDBm8bLS0nZaiNEIJbRomT0gpg3tNWSNZqJ71vmSd1w-kJupm8m227dtaUjCWY2vRhrfsnlXRQ_05iWKll-qVoLTEmdRFcvgj69Lh1eVDrkI3rOh1d2maFGWc1MNLIgl5M6FJ3ToWytGI0I67mVFAqSCNG6t1EmT7l3Du_C4NBjYWpsTA1FVbo89f5d-zfegrwdgJWIVr9O_yfzRXEef0KBkZLuGf13qbH</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Cherwonogrodzky, John W.</creator><creator>Yu, Justin</creator><creator>Lillico, Dustin</creator><creator>Hu, Charles Chen</creator><creator>Chau, Damon</creator><creator>Yin, Junfei</creator><creator>Hu, Wei-Gang</creator><creator>Negrych, Laurel M.</creator><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</title><author>Cherwonogrodzky, John W. ; Yu, Justin ; Lillico, Dustin ; Hu, Charles Chen ; Chau, Damon ; Yin, Junfei ; Hu, Wei-Gang ; Negrych, Laurel M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal, Murine-Derived - immunology</topic><topic>Antibodies, Monoclonal, Murine-Derived - pharmacology</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Neutralizing - pharmacology</topic><topic>Antibody Affinity</topic><topic>Antidotes</topic><topic>Antitoxins - immunology</topic><topic>Antitoxins - pharmacology</topic><topic>Drug therapy</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monoclonal antibodies</topic><topic>Poisoning</topic><topic>Protein Structure, Tertiary</topic><topic>Ricin</topic><topic>Ricin - immunology</topic><topic>Ricin - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cherwonogrodzky, John W.</creatorcontrib><creatorcontrib>Yu, Justin</creatorcontrib><creatorcontrib>Lillico, Dustin</creatorcontrib><creatorcontrib>Hu, Charles Chen</creatorcontrib><creatorcontrib>Chau, Damon</creatorcontrib><creatorcontrib>Yin, Junfei</creatorcontrib><creatorcontrib>Hu, Wei-Gang</creatorcontrib><creatorcontrib>Negrych, Laurel M.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cherwonogrodzky, John W.</au><au>Yu, Justin</au><au>Lillico, Dustin</au><au>Hu, Charles Chen</au><au>Chau, Damon</au><au>Yin, Junfei</au><au>Hu, Wei-Gang</au><au>Negrych, Laurel M.</au><au>Byrne, Barry J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Ricin is a potential biothreat agent with no approved antidote available for ricin poisoning. The aim of this study was to develop potent antibody-based antiricin antidotes. Four strong ricin resistant hybridoma clones secreting antiricin monoclonal antibodies (mAbs) were developed. All four mAbs are bound to conformational epitopes of ricin toxin B (RTB) with high affinity (KD values from 2.55 to 36.27 nM). RTB not only triggers cellular uptake of ricin, but also facilitates transport of the ricin toxin A (RTA) from the endoplasmic reticulum to the cytosol, where RTA exerts its toxic activity. The four mAbs were found to have potent ricin-neutralizing capacities and synergistic effects among them as determined by an in vitro neutralization assay. In vivo protection assay demonstrated that all four mAbs had strong efficacy against ricin challenges. D9 was found to be exceptionally effective. Intraperitoneal (i.p.) administration of D9, at a dose of 5 μg, 6 weeks before or 6 hours after an i.p. challenge with 5 × LD50 of ricin was able to protect or rescue 100% of the mice, indicating that mAb D9 is an excellent candidate to be developed as a potent antidote against ricin poisoning for both prophylactic and therapeutic purposes.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>23484120</pmid><doi>10.1155/2013/471346</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2013-01, Vol.2013 (2013), p.1-9
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3591125
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Animals
Antibodies, Monoclonal, Murine-Derived - immunology
Antibodies, Monoclonal, Murine-Derived - pharmacology
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - pharmacology
Antibody Affinity
Antidotes
Antitoxins - immunology
Antitoxins - pharmacology
Drug therapy
Epitopes - immunology
Female
Health aspects
Mice
Mice, Inbred BALB C
Monoclonal antibodies
Poisoning
Protein Structure, Tertiary
Ricin
Ricin - immunology
Ricin - toxicity
title Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A13%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conformation-Dependent%20High-Affinity%20Potent%20Ricin-Neutralizing%20Monoclonal%20Antibodies&rft.jtitle=BioMed%20research%20international&rft.au=Cherwonogrodzky,%20John%20W.&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2013/471346&rft_dat=%3Cgale_pubme%3EA373372879%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c500t-400c3b05069da010fd8a9d62500ac7776d432e99d704ff3b794bae9ffb4f25863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1464504289&rft_id=info:pmid/23484120&rft_galeid=A373372879&rfr_iscdi=true